<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[ARTMS Inc. and Telix Pharmaceuticals Limited 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=36819></link><description><![CDATA[ARTMS Inc. and Telix Pharmaceuticals Limited 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Tue, 05 May 2026 03:30:40 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2021/01/12_3554238800_20210113155625_3944127769.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[ARTMS and Telix Pharmaceuticals Announce Successful Production of PSMA-11 with Cyclotron Produced 68Ga from a Solid Target]]></title><link>https://www.newswire.co.kr/newsRead.php?no=917196</link><description><![CDATA[BURNABY, British Columbia & INDIANAPOLIS--(Business Wire/Korea Newswire)--ARTMS Inc. (‘ARTMS’) and Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) are pleased to announce they have successfully produced Telix’s prostate cancer imaging product, TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)[1], using multi-Curie quantities of cyclotron-produced Gallium-68 (68Ga) via ARTMS’ proprietary Quantum Irradiation System...]]></description><pubDate>Wed, 13 Jan 2021 16:10:00 +0900</pubDate></item><item><title><![CDATA[ARTMS와 텔릭스 파마슈티컬스, 고형 표적으로 사이클로트론에서 생산된 갈륨-68 통해 PSMA-11 생산 성공]]></title><link>https://www.newswire.co.kr/newsRead.php?no=917197</link><description><![CDATA[버나비, 브리티시 컬럼비아/인디애나폴리스--(Business Wire/뉴스와이어)--ARTMS(ARTMS Inc.)와 텔릭스 파마슈티컬스(Telix Pharmaceuticals Limited)(호주증권거래소: TLX, 이하 텔릭스)가 전립선암 이미징 조영제인 TLX591-CDx(68Ga-PSMA-11 준비 키트)[1]를 성공적으로 생산했다고 발표했다.  이번 생산은 ARTMS의 독자적인 고형 표적시스템인 QIS®(Quantum Irradiation System)를 통해 사이클로트론에서 생산된 멀티퀴리(multi-Curie) 수준의 갈...]]></description><pubDate>Wed, 13 Jan 2021 16:10:00 +0900</pubDate></item></channel></rss>